SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

SMS Pharmaceuticals receives EIR from USFDA for API facility in Andhra Pradesh

12 Mar 2020 Evaluate

SMS Pharmaceuticals has received Establishment Inspection Report (EIR) from United States Food and Drug Administration (USFDA) for its API facility situated at Kandivalasa, Andhra Pradesh. The USFDA had inspected the said facility during the period January 13, 2020 to January 17, 2020. This facility predominantly caters regulated markets including USA.

SMS Pharmaceuticals is a global player in API manufacturing having strong research and manufacturing team supported by state of art facilities.

SMS Pharmaceuticals Share Price

414.90 -5.70 (-1.36%)
08-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×